ArticleNeuro-oncology advances
HR+/HER2- breast cancer brain metastases treated with definitive local therapy: a focus on endocrine sensitivity and incidence of leptomeningeal disease.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinicopathological factors associated with brain metastases development among breast cancer patients receiving neoadjuvant chemotherapy.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain metastases (BrM) among patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) are understudied. We sought to understand the endocrine sensitivity of patients with HR+/HER2- BrM and determine the associated risk of leptomeningeal metastatic disease (LMD). Methods: We conducted a retrospective cohort study of 204 consecutive patients (≥18 yr of age) with HR+/HER- mBC who were treated for BrM at the Sunnybrook Odette Cancer Centre between 2008 and 2018. We used descriptive statistics to summarize patient and treatment characteristics and Kaplan-Meier analyses for survival outcomes. The log-rank test was used to compare outcomes of patients with endocrine-sensitive versus endocrine-resistant disease. Results: Among 204 patients with HR+/HER2- BrM, the median age at BrM diagnosis was 56 years (range, 48-64), and the median time between diagnosis of mBC to development of BrM was 15 months (interquartile range [IQR], 3-36). At the time of BrM development, 160 patients (78.4%) had endocrine-resistant disease, and 28 patients (13.7%) had endocrine-sensitive disease; endocrine sensitivity of the remaining 16 patients (7.8%) was unknown. In total, 58 patients (28.4 %) developed LMD with a median time from BrM to LMD of 10.8 months (IQR, 3.1-14.8). Patients with endocrine-sensitive disease at the time of BrM diagnosis had a longer brain-specific progression-free survival (7 mo versus 5 months, Conclusions: Most patients with HR+/HER2- BrM have endocrine-resistant disease, with an unexpectedly high likelihood of developing LMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.